FDA Media Advisory: FDA Issues Warning Letters for Drugs Promoted in Fat Elimination Procedure
** CREDENTIALED MEDIA ONLY **
A briefing on FDA's warning to several medical spas that the cosmetic procedure known as lipodissolve has not been approved for use as a fat-removing procedure, and its safety and effectiveness is unknown.
- Kathleen Anderson, deputy director, Division of New Drugs and Labeling Compliance, Office of Compliance, CDER
- Sudha Shukla, pharmacist, Division of New Drugs and Labeling Compliance, Office of Compliance, CDER
- Samia Nasr, team leader, Division of New Drugs and Labeling Compliance, Office of Compliance, CDER
- Edisa Gozun, pharmacist, Division of New drugs and Labeling Compliance, Office of Compliance, CDER
Wednesday, April 7, 2010, 2:00 p.m. EDT
Reporters in the United States can participate by calling 800-857-5159. International callers will need to dial 415-228-4647. The passcode is "FDA."
A replay of the briefing will be available approximately one hour after the event ends until April 14, 2010, at midnight, EDT. To hear the replay, callers in the United States can dial 866-448-4799. International callers can dial 203-369-1173. The passcode is 7050.
CONTACT: Tom Gasparoli, +1-301-796-4737, email@example.com
/PRNewswire-USNewswire -- April 7/
SOURCE U.S. Food and Drug Administration